Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Johnson & Johnson JNJ

Healthcare  —  Drug Manufacturers General
271.22 0.54 0.20% as of 25 Sep
Market cap
$652.8B
P/E
31.4×
S&P 500 Member Dividend Aristocrat Cash Flow Champion (3y) Revenue Champion (3y) Insider Buys (last 12m)
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Johnson & Johnson (JNJ) Return on invested capital

Johnson & Johnson's return on invested capital over the twelve months to 30 June 2026 was 15.5%, down 4.7 percentage points from fiscal 2025 (20.2%). Over the past ten years it has ranged from 13.1% (fiscal 2023) to 26.3% (fiscal 2015); the current reading is higher than 82% of that period. That is above the Drug Manufacturers General industry median of 6.30% and above the Healthcare sector median of 0.00%.

Return on invested capital, annual

Annual

Period Return on invested capital Change (points)
FY2025 20.2% 6.75
FY2024 13.4% 0.32
FY2023 13.1% (1.74)
FY2022 14.9% (1.70)
FY2021 16.6% 1.98
FY2020 14.6% (1.66)
FY2019 16.2% (0.36)
FY2018 16.6% 1.37
FY2017 15.2% (9.06)
FY2016 24.3% (2.00)

Against its own ten years

Low 13.1% High 26.3%
Ten-year median 16.2%
Current reading's percentile 82

Return on invested capital against peers

Company Return on invested capital
LLY Eli Lilly and Company compare 26.3%
ABBV AbbVie Inc. compare 18.1%
JNJ Johnson & Johnson 15.5%
NVS Novartis AG compare 13.1%
AMGN Amgen Inc. compare 13.0%
AZN AstraZeneca PLC compare 11.7%
PFE Pfizer Inc. compare 6.30%
MRK Merck & Co., Inc. compare 5.08%
GILD Gilead Sciences, Inc. compare −4.48%
Drug Manufacturers General industry median 6.30%
Healthcare sector median 0.00%
Market median 0.00%

What Return on invested capital is

Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.

TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)

The full definition of Return on invested capital →

More on JNJ